0001178913-25-0004376-K Evogene Ltd. 20250212202502121601541601551601550 0001178913-25-000437 6-K 1 20250212 20250212 20250212 Evogene Ltd. 0001574565 2870 000000000 L3 1231 6-K 34 001-36187 25614694 13 GAD FEINSTEIN STREET PARK REHOVOT REHOVOT L3 7638517 97289311900 13 GAD FEINSTEIN STREET PARK REHOVOT REHOVOT L3 7638517 6-K 1 zk2532711.htm 6-K UNITED STATES Â SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Â REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the month of February 2025 Â Commission File Number 001-36187 EVOGENE LTD. Â Â (Translation of Registrantâ€™s Name into English) Â 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel Â Â (Address of principal executive offices) Â Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Â Form 20-F â˜’Â Form 40-F â˜Â Â CONTENTS Â Evogene Ltd. (theÂ â€œRegistrantâ€ or the â€œCompanyâ€) hereby announces that the shareholders of the Company approved the proposal brought before the special general meeting of shareholders held on February 12, 2025 (following a one-week adjournment from the original meeting date) (the â€œMeetingâ€), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Companyâ€™s articles of association, as described in theÂ Proxy Statement which was attached as Exhibit 99.2 to the Companyâ€™s Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (â€œSECâ€), on December 30, 2024, and sent in connection with the Meeting. The contents of this Report of Foreign Private Issuer on Form 6-K (this â€œForm 6-Kâ€) is incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565), and Form S-8 (SEC File Nos. 333-193788,Â 333-201443,Â 333-203856Â andÂ 333-259215) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Â Â SIGNATURE Â Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Date: February 12, 2025 Â EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad â€”â€”â€”â€”â€”â€”â€”â€”â€”â€”â€”â€”â€”â€” Yaron Eldad Chief Financial Officer Â Â Â